I think you asked about the innovative therapies. They're for a lot of different disease categories. I think the common factor is that they're mostly considered to be “first in class” so they're a new therapy. They are for cancers and some of the rare disorders. We've had some breakthrough therapies for diabetes as well. The problem, as we said, is that the common drug review process uses a very narrow yardstick. If it is a therapy, they compare it to an existing therapy. If it's cheaper than the existing therapy, they will approve it.
Their process is inherently biased, so drugs that primarily get recommended are those for which there's already a category of drugs. They compare them and just compare the costs. They're already biased against drugs coming in for which they don't have an automatic cost comparison.
The other thing they look at is long-term evidence in clinical outcomes. When you're a new therapy, a first in class, you're not going to have those. These are often therapies for people who may be resistant to the current treatments. For instance, with the renal cancer groups, these are patients who actually have very advanced kinds of cancer for which no other therapies are available. Nexavar, for instance, was the first new treatment for kidney cancer in 12 years. Again, there isn't that long-term evidence.
So the process they use, which they seem to be very proud of, in fact uses a very narrow set of assessment tools, when in reality health technology assessment includes a whole range of tools that they absolutely ignore.